Premium
P1‐178: Impact of Co‐Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders
Author(s) -
Prins Niels D.,
Bergeron David,
Groot Colin,
Loenhoud Anita C.,
Laforce Robert,
Berckel Bart N.M.,
Barkhof Frederik,
van der Flier Wiesje M.,
Scheltens Philip,
Ossenkoppele Rik
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.926
Subject(s) - dementia , medicine , cohort , neuropsychology , pathology , vascular dementia , amyloid (mycology) , cognition , disease , gastroenterology , oncology , psychiatry
significantly more accurate than Tau in discriminating AD from MCI. Final analysis incorporating all studies up to 2015 will be presented. Conclusions: CSF biomarkers have good sensitivity and specificity, especially since most studies were based on clinically evaluated cohorts, meaning a proportion of controls will have preclinical AD, and some patients with non-AD dementia will have AD or concomitant AD pathology. CSF biomarker ratios have greater diagnostic accuracy than single biomarkers.